trending Market Intelligence /marketintelligence/en/news-insights/trending/trms8cG9b5JaeV5Tgcqwvg2 content esgSubNav
In This List

Global Blood Therapeutics plans $100M common stock offering

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Global Blood Therapeutics plans $100M common stock offering

Global Blood Therapeutics Inc. plans to sell $100 million of common stock in a registered underwritten public offering.

The company granted the underwriter an option to buy up to $15 million of its common stock.

Global Blood plans to use the net proceeds to fund the clinical development of voxelotor for treating sickle cell disease, and other clinical trials. It also intends to use the net proceeds for other research and development activities, working capital and general corporate purposes.

Cantor Fitzgerald & Co. is acting as the sole book-running manager for the offering.